Home

MacroGenics, Inc. - Common Stock (MGNX)

1.7800
+0.1400 (8.54%)
NASDAQ · Last Trade: Jun 10th, 6:18 PM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close1.640
Open2.010
Bid1.760
Ask1.800
Day's Range1.780 - 2.170
52 Week Range0.9897 - 5.770
Volume25,808,478
Market Cap108.77M
PE Ratio (TTM)-2.000
EPS (TTM)-0.9
Dividend & YieldN/A (N/A)
1 Month Average Volume435,482

Chart

About MacroGenics, Inc. - Common Stock (MGNX)

Macrogenics is a biotechnology company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and other serious diseases. The company’s research and development efforts aim to harness the power of the immune system to fight tumors, utilizing advanced technologies to engineer molecules that can specifically target and modulate tumor-associated antigens. Macrogenics collaborates with various partners to advance its pipeline of proprietary and partnered programs, including therapies that are currently undergoing clinical trials, with the goal of providing new treatment options for patients with unmet medical needs. Read More

News & Press Releases

Synergy CHC (NASDAQ: SNYR) Taps Coca-Cola Exec to Accelerate Global Expansion of “FOCUSfactor®” Energy Drink – More Stocks Moving Inside
Synergy CHC Corp. (NASDAQ: SNYR), a fast-rising force in the consumer health and wellness space, has appointed Damian Marano as Vice President of Beverage in a strategic move aimed at catapulting the company’s FOCUSfactor Energy Drink into global markets. Marano, a seasoned executive with a decorated history at The Coca-Cola Company (NYSE: KO), brings a wealth of expertise that could unlock powerful international distribution opportunities for the brand.
Via AB Newswire · June 10, 2025
Power Metallic (TSXV: PNPN) (OTCQB: PNPNF) Positioned for Critical Minerals Breakout Following Acquisition – More Stocks Inside
Power Metallic Mines Inc. (TSXV: PNPN) (OTCQB: PNPNF) has executed a deal to acquire 100% of 313 mineral claims from Li-FT Power Ltd., expanding its Quebec land position by over 300% to 212.86 km² . The newly acquired claims border the Company’s flagship Nisk Project, surrounding the high-grade Nisk, Lion, and Tiger polymetallic discoveries.
Via AB Newswire · June 10, 2025
Which stocks are gapping on Tuesday?chartmill.com
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps.
Via Chartmill · June 10, 2025
A Look at Macrogenics's Upcoming Earnings Reportbenzinga.com
Via Benzinga · May 12, 2025
Peeling Back The Layers: Exploring Macrogenics Through Analyst Insightsbenzinga.com
Via Benzinga · November 7, 2024
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · June 10, 2025
MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement
By MacroGenics, Inc. · Via GlobeNewswire · June 10, 2025
MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
ROCKVILLE, MD, June 03, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company’s management team will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tuesday, June 10, 2025, at 8:00am ET in Miami, FL.
By MacroGenics, Inc. · Via GlobeNewswire · June 3, 2025
4 Analysts Assess Macrogenics: What You Need To Knowbenzinga.com
Via Benzinga · May 20, 2025
Macrogenics Earnings Previewbenzinga.com
Via Benzinga · November 4, 2024
Earnings Scheduled For May 13, 2025benzinga.com
Via Benzinga · May 13, 2025
MacroGenics Announces Date of First Quarter 2025 Financial Results
ROCKVILLE, MD, May 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the first quarter of 2025 after the market closes on Tuesday, May 13, 2025. 
By MacroGenics, Inc. · Via GlobeNewswire · May 6, 2025
MacroGenics to Participate in Upcoming Investor Conference
ROCKVILLE, MD, May 01, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company's management team will participate in the following investor conference this month:
By MacroGenics, Inc. · Via GlobeNewswire · May 1, 2025
Why AZEK Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · March 24, 2025
MacroGenics (MGNX) Q4 2024 Earnings Call Transcriptfool.com
MGNX earnings call for the period ending December 31, 2024.
Via The Motley Fool · March 20, 2025
Earnings Scheduled For March 20, 2025benzinga.com
Via Benzinga · March 20, 2025
MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call
ROCKVILLE, MD, March 06, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the fourth quarter and full year of 2024 after the market closes on Thursday, March 20, 2025. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Thursday, March 20, 2025, at 4:30 pm ET
By MacroGenics, Inc. · Via GlobeNewswire · March 6, 2025
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD, Feb. 27, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences in March:
By MacroGenics, Inc. · Via GlobeNewswire · February 27, 2025
MGNX ALERT: Bragar Eagel & Squire, P.C. is Investigating Macrogenics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Macrogenics, Inc. (NASDAQ: MGNX) on behalf of long-term stockholders following a class action complaint that was filed against MGNX on July 26, 2024 with a Class Period from March 7, 2024 to May 9, 2024. Our investigation concerns whether the board of directors of MGNX have breached their fiduciary duties to the company.
By Bragar Eagel & Squire · Via GlobeNewswire · December 10, 2024
MacroGenics to Participate in Upcoming Investor Conference
ROCKVILLE, MD, Dec. 02, 2024 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conference this month:
By MacroGenics, Inc. · Via GlobeNewswire · December 2, 2024
MacroGenics (MGNX) Q3 2024 Earnings Call Transcriptfool.com
MGNX earnings call for the period ending September 30, 2024.
Via The Motley Fool · November 5, 2024
MacroGenics to Participate in Upcoming Investor Conferences
ROCKVILLE, MD, Nov. 06, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conferences this month:
By MacroGenics, Inc. · Via GlobeNewswire · November 6, 2024
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · November 6, 2024
MacroGenics Announces Leadership Transition
ROCKVILLE, MD, Oct. 30, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that Scott Koenig, M.D., Ph.D., intends to step down as President and Chief Executive Officer early next year. The Company’s Board of Directors has retained Heidrick & Struggles to lead a search process to identify its next Chief Executive Officer and has established a special committee of the Board to oversee the transition process.
By MacroGenics, Inc. · Via GlobeNewswire · October 30, 2024
MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call
ROCKVILLE, MD, Oct. 29, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial results for the third quarter of 2024 after the market closes on Tuesday, November 5, 2024. MacroGenics will host a conference call to discuss the financial results and recent corporate progress on Tuesday, November 5, 2024, at 4:30 pm ET.
By MacroGenics, Inc. · Via GlobeNewswire · October 29, 2024